KAYS is launching psychedelic-assisted therapy, Fifth Dimension Therapeutics FDT, for treatment of PTSD, addictions, eating disorders, and other treatment-resistant mental health disorders.
A senior employee of KAYS Bryan Arnold, enrolled in a training course to obtain an Oregon psilocybin facilitator s license that will allow him to legally oversee the cultivation of psilocybin mushrooms and related products, as well as operate up to five state-licensed psilocybin administration clinics.
KAYS is moving into psychedelics therapy by adding experienced attorney Glenn E.J.. Murphy was asked to establish relationships with pharmaceutical companies, develop IP and joint ventures, funding opportunities and acquisitions on FDT's board of directors.
KAYS is one of many companies that are uniquely qualified to deliver the highest quality of care to patients in need, according to senior advisor W. David Jones, who said the operation of a psychedelics treatment establishment has many parallels to the cannabis industry.
Craig Frank, CEO, said we have shifted our cannabis operations to the European market, where we believe that a substantial market exists without the regulatory burdens of the fragmented and nationally stymied U.S market. I believe that we have an excellent opportunity to take a leadership role in the mind care market because of all we have learned from our cannabis operations in the psychedelics market. Kaya Holdings has four majority-owned subsidiaries in both the cannabis and psychedelic industries.
Photo: Benzinga edit with photo by pdsci on Shutterstock and Wikimedia Commons.